Cell Therapy Market Report: Information By Type (Autologous & Allogeneic), By Product (Consumables (Vessel/Media/Serum/Reagent), Equipment, & Software & Other Services), Technique, By End User (Hospitals & Clinics & Others) - Forecast 2027
|ID: VPR/HC/1097||Publishing Year: January 2022||Pages: 106||Format:|
Cell Therapy Market Overview:
Biotechnology developments have resulted in the adoption of tailored treatments for a wide spectrum of conditions. Chronic diseases such as cancer, neurological disorders, and genetic disorders are being treated with stem cell therapy. Furthermore, the benefits of Cell Therapy, such as tailored treatment, faster and more efficient recovery, and less side effects, encourage the use of a variety of products. Because FDA-approved products are readily available in North America, cell treatments are commonly used. For example, the FDA granted Novartis' Kymriah regenerative medicine advanced therapy designation in April 2020 for the treatment of refractory (r/r) follicular lymphoma (FL) in adults. The FDA authorisedbrexucabtageneautoleucel (Tecartus), a CAR T-cell treatment for patients with mantle cell lymphoma, in July 2020. It was approved through the Accelerated Approval procedure and is the first FDA-licensed CAR T-cell treatment for mantle cell lymphoma. Tecartus has also been designated as an Orphan Drug, which promotes the development of treatments for uncommon disorders. Kymriah for acute lymphoblastic leukaemia and Yescarta for diffuse large B-cell lymphoma are the other authorised CAR-T cell treatments for cancer. Aside from that, with over 250 clinical trials examining CAR T-cell therapies around the world, more cell therapies are on the way, with possible indications including pancreatic cancer, autoimmune illnesses, Alzheimer's disease, and Parkinson's disease. The cell treatment market is projected to be driven by this.
- Syngenta AG (Switzerland)
- Kitazawa Seed Company (US)
- Maharashtra Hybrid Seeds Company Private Limited (India)
- Sakata Seed Corporation (Japan)
- W. Atlee Burpee& Co (US)
- Alabama Farmers Cooperative, Inc (US)
- Western Bio Vegetable Seeds Ltd (India)
- UPL Limited (India)
- Mahindra Agri Solutions Pvt. Ltd (India)
- Terra Agro Biotech Pvt. Ltd (India)
Furthermore, market growth has been assisted by the gradual appearance of new technologies to promote the development of innovative therapies. The introduction of proprietary cell lines is widely regarded as the most effective way to use a single product to generate a large number of candidates. Immunicum, for example, uses Chimeric Antigen Receptor T cell (CAR-T) expansion, dendritic cell neoantigen presentation technology, and T-cell primers to enhance its immuno-oncology product line.
The Stem Cell Category dominated the worldwide cell treatment market in 2019, and this trend is expected to continue during the forecast period, as these therapies gain acceptance as a result of government initiatives. The number of Stem Cell Banks is increasing in developing countries, which is fueling the expansion of the cell treatment industry. Furthermore, increased awareness of Stem Cell Preservation has a positive impact on the cell therapy market. Furthermore, in 2019, the allogenic therapy segment led the market by therapy type. This therapy is advantageous because it involves the generation of one's own immune stem cells, which may be able to kill cancer cells that persist even after treatment with high-dose cytotoxic medicines. Allogeneic transplants are advised for patients who have a high risk of relapse following effective chemotherapy treatment. As a result, the global market for allogeneic therapy is being fueled by an increase in cancer relapse cases. During the projection period, the malignancies segment is expected to lead the global market by therapeutic area. Major factors driving the cell therapy market growth include an increase in cancer research, an increase in the global geriatric population, and an increase in the acceptance of Cell Therapy for the treatment of malignancies.
The rise in the number of startups in the healthcare industry is expected to boost the APAC Cell Therapy Market over the forecast period. Furthermore, rising demand for modern drugs from a large number of people suffering from degenerative diseases is expected to promote market growth in the near future.
The pandemic has had a detrimental influence on the Cell Treatment Sector, as most governments have implemented lockdown measures to battle the outbreak. In addition, most clinics throughout the world have halted new Stem Cell Therapy, organ transplant, and other therapies for the next six months, at least until the situation appears to be under control. Clinical trial delays have also been revealed by biopharmaceutical companies, including significant heavyweights such as Pfizer and Eli Lilly. Allogeneic cell treatments, or cell therapies taken from a healthy donor, are especially vulnerable. Furthermore, allogeneic donors are less likely and frequently unable to donate their cells due to social distance constraints. This causes delays in cell collection, which affect the entire process of allogeneic cell treatment. As the ongoing investigation of COVID-19 cases reveals that persons with underlying illnesses are disproportionately afflicted by the virus, many patients who do not require emergency treatment are opting to wait rather than risk infection. Furthermore, patients are already being prioritised based on their risk and need. To allow treatment and trials to continue, various country and region-specific conditions have been imposed; nonetheless, many ongoing trials and readouts have been postponed, and future trials have been completely halted.
Type Here for table of content.